
“This patent opens a totally new field for using our shock wave technology in the most advanced medical treatments that employ stem cells for tissue reconstruction,” commented Kevin Richardson, chairman of the board of directors of Sanuwave.
“The total market for stem cell research products, stem cell antibodies and stem cell therapies was $5.7 billion in 2011 and has a potential to reach $8.8 billion by 2016. Our technology can play a role in this market, especially since successful confirmatory work of the subject of this patent has been done by a team at Harvard University. Using Sanuwave’s devices in two different animal models, these scientists demonstrated the effects of shock waves on stimulation inside the body of donor stem cells, which were harvested, implanted and successfully produced viable tissue regeneration. This work has been published in two peer-reviewed journals,” concluded Richardson.
Sanuwave now has 38 patents (issued or pending) on focused shock waves in medical and non-medical applications.
Date: May 20, 2014
Source: Sanuwave Health
Filed Under: Drug Discovery